Global funding cuts reversing decades of tuberculosis progress, WHO says
Ahead of World Tuberculosis Day on 24 March, the World Health Organization (WHO) has said that cuts in global funding…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Unsafe and unregulated cell therapies being sold in Europe
The European Medicines Agency (EMA) has issued a warning about the dangers of unregulated advanced therapy medicinal products (ATMPs) being…
-
Vivani treats first patient with long-lasting drug implant for weight loss
A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the…
-
Why pharma is still far from a treatment for galactosemia
Nearly three months after an experimental treatment for classic galactosemia was rejected by the US Food and Drug Administration (FDA),…
-
Novo Nordisk plans new study for CagriSema, targets 2026 submission
Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential…
-
Glucotrack hits trial success for direct blood measuring CGM
Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures glucose levels from a…
-
WHO’s Neglected Tropical Disease Day at unfamiliar odds with US stance
The World Health Organization (WHO) has called for country commitment to combat neglected tropical diseases, as the agency braces itself…
-
Allurion shares soar 77% after sharing plans for GLP-1RA combo trial
If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans…
-
Atara’s T cell programmes hit with clinical hold after third-party site woes
Atara Therapeutics’ pipeline has hit another obstacle after the US Food and Drug Administration (FDA) halted clinical trials evaluating two…
-
Pulse Biosciences touts positive results from PFA early feasibility study
Pulse Biosciences has reported positive results from a first-in-human feasibility study evaluating its nanosecond pulsed field ablation (nsPFA) technology for…
